Literature DB >> 15498677

Stereoselective inhibition of glutamate carboxypeptidase by organophosphorus derivatives of glutamic acid.

Jeremy P Mallari1, Cindy J Choy, Ying Hu, Alicia R Martinez, Mia Hosaka, Yoko Toriyabe, Jack Maung, Joseph E Blecha, Stephen F Pavkovic, Clifford E Berkman.   

Abstract

A series of alkyl and aryl phosphonyl, thiophosphonyl, and dithiophosphonyl derivatives of (S)- and (R)-glutamic acid were prepared and examined for inhibitory potency against glutamate carboxypeptidase (carboxypeptidase G). The acquisition of the phosphonamidodithioic acids and the individual phosphonamidothioic acid diastereomers was achieved through a common phosphonamidothiolate precursor, which also allowed for the chromatographic resolution of the chiral phosphorus center of the phosphonamidothioic acids. The most potent inhibitor of the series was the n-butylphosphonamidate derivative of the natural isomer of glutamic acid. Although each diastereomeric pair of three phosphonamidothionates exhibited stereoselective inhibition consistent with the configuration of the chiral phosphorus center, this effect was generally not remarkable. More important, was the effect of carbon stereochemistry upon glutamate carboxypeptidase inhibition as exemplified by a limited series of enantiomeric pairs of phosphonamidate and phosphonamidodithionate derivatives of glutamic acid. The phosphonamidate analogs derived from the unnatural stereoisomer of glutamic acid were devoid of inhibitory potency in contrast to their enantiomers. Surprisingly, the phosphonamidodithionates derived from the unnatural stereoisomer of glutamic acid demonstrated greater inhibitory potency than their naturally-derived antipodes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15498677     DOI: 10.1016/j.bmc.2004.08.016

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Design and synthesis of a siderophore conjugate as a potent PSMA inhibitor and potential diagnostic agent for prostate cancer.

Authors:  Pingyu Ding; Paul Helquist; Marvin J Miller
Journal:  Bioorg Med Chem       Date:  2007-11-17       Impact factor: 3.641

2.  Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.

Authors:  Suzanne E Lapi; Hilla Wahnishe; David Pham; Lisa Y Wu; Jessie R Nedrow-Byers; Tiancheng Liu; Kaveh Vejdani; Henry F VanBrocklin; Clifford E Berkman; Ella F Jones
Journal:  J Nucl Med       Date:  2009-11-12       Impact factor: 10.057

3.  Evaluation of radioiodinated protein conjugates and their potential metabolites containing lysine-urea-glutamate (LuG), PEG and closo-decaborate(2-) as models for targeting astatine-211 to metastatic prostate cancer.

Authors:  Yawen Li; Ming-Kuan Chyan; Donald K Hamlin; Holly Nguyen; Robert Vessella; D Scott Wilbur
Journal:  Nucl Med Biol       Date:  2020-05-03       Impact factor: 2.408

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.